Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Helion Biotech ApS
Lyngby, Capital Region of Denmark, Denmarkhelionbiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Helion Biotech has a Phase II-ready replacement therapy with recombinant human MBL (rhMBL) for treating inherited immune defects. The therapy is supported by over 10 independent clinical publications since 2006 linking MBL deficiency to high risk of neonatal infection and sepsis. A complete US regulatory dossier enables direct entry into a Phase II clinical trial, and additional expansion to other immunocompromised indications is proposed.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Recombinant protein
- Industry
- Biotech
Beyond the preview
Go deeper on Helion Biotech ApS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helion Biotech ApS.